News
Read the latest from M8.
Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL
Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS
Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America
Jul 20, 2021
Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America
Jul 06, 2021
Marinomed Biotech AG Grants Exclusive Rights for Carragelose® to M8 Pharmaceuticals marketed locally as Barlo®
Jun 22, 2021
M8 Pharmaceuticals and UCB partner for Central Nervous System and Respiratory Portfolio in Mexico.
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.